Schedule Now Pay Bill
be_ixf;ym_202406 d_18; ct_50

Spravato® Nasal Spray

Spravato® is a brand name for esketamine nasal spray and, like Ketamine Infusion Therapy, causes neuroplasticity in the brain that has a healing effect for some mental disorders. Ketamine and esketamine both have different outcomes in different people, your care team at Beacon Medical Group will discuss both options and offer the treatment that is most effective for your unique needs.

Is Spravato® right for you?

This prescription nasal spray medicine used alongside an oral antidepressant has proven effective for adults with treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior (MDSI).

How is SPRAVATO® different from Ketamine Infusion Therapy?

While ketamine is administered via slow intravenous infusion, esketamine is inhaled through the nose (i.e., intranasal). Esketamine works on a different molecule from ketamine but on the same receptor, NMDA.

How does SPRAVATO® work?

SPRAVATO® targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. Many scientists believe this receptor is the key to reversing the neuron damage caused by depression and anxiety.

What can I expect from SPRAVATO® treatment?

Beacon Medical Group is a certified SPRAVATO® treatment center. You’ll need to plan for rides to and from the office. To help ensure the safe and appropriate use of SPRAVATO®, You will administer SPRAVATO® yourself under the supervision of a healthcare provider, who will show you how to use the SPRAVATO® nasal spray device. You’ll take SPRAVATO® twice a week for the first month. During the second month, you’ll take it once a week. After that, you’ll take it once a week or once every two weeks.

Is SPRAVATO® nasal spray safe?

SPRAVATO® nasal spray was evaluated for safety in both short- and long-term clinical trials of adults diagnosed with treatment-resistant depression.

Which disorders are treated with SPRAVATO®?

  • Treatment-Resistant Depression (TRD)
  • Major Depressive Disorder (MDD) with acute suicidal ideation or behavior (MDSI).